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However, the Bland Altman plot of APCO versus ICO shows a wide spread of data points with a percentage error of 42%. These large variations could lead to a completely different clinical management. Also, we disagree that a percentage error less than 28% is a conservative requirement. By using an error-gram, limits of precision of ±20% for both test and reference method give predicted limits of agreement of 28.3% [2] . These limits should be respected when an alternative cardiac output measurement technique is evaluated because limits of precision in excess of 20% for a single technique are not clinically acceptable.
Furthermore, the authors state that they only consider a change in cardiac output of 30% or more clinically relevant. This is in contrast to daily clinical practice in which cardiac output changes of 10% to 15% are frequently used for making decisions regarding therapy. Also, they have calculated the change in cardiac output by dividing the delta cardiac output by the mean value before and after the change. In this way they have artificially decreased the relative change in cardiac output. Subsequently, in the plot showing the change in ICO versus the change in APCO, it can be observed that when changes in ICO of more than 15% are analyzed, in only 35% of the cases did the APCO also change 15% or more in the same direction. Moreover, in 45% of the cases the APCO changed in the opposite direction! Based on the results of this study, we think that APCO is not accurate in measuring absolute values of cardiac output, nor in tracking changes in cardiac output in a general intensive care population.
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Few data support the use of any therapy based on hemodynamic variables to improve outcome in intensive care unit (ICU) patients. In the recently completed FACTT trial, therapy based on cardiac output had no impact on patient outcome [3] . Other trials targeting cardiac output as a treatment variable have had disappointing results [4] .
In our study of ICU patients exhibiting a broad range of physiological variability, the limits of precision for ICO are ±36% simply for consecutive measures of ICO. Our ICO measurements are likely to reflect greater precision than usual practice as the investigators would frequently obtain additional (more than four) measurements in an attempt to maximize reliability of the ICO data during the trial, selecting the four measures in best agreement. In two trials involving more homogeneous groups of patients precision was similar [5, 6] .
A change in cardiac output of 15% or less should not prompt a change in management by itself. Basing treatment decisions on cardiac output changes of 10% to 15% likely results in unnecessary hemodynamic manipulation of unknown clinical impact and we would strongly discourage this practice in the absence of other clinically relevant information [7] .
Both continuous methods (continuous cardiac output [CCO] and APCO) track dynamic change in cardiac output utilizing ICO as a reference in a remarkably similar fashion. Although the absolute magnitude of cardiac output change with either continuous measure is rarely identical to a simultaneous ICO measurement, both continuous methods track ΔICO acceptably well within ±30% (96% of the time for APCO and 95% of the time for CCO using this well accepted technology). Breukers and colleagues [5] found concordance of delta cardiac output in 75% of determinations comparing ICO to APCO.
APCO is a promising minimally invasive technology that offers great safety advantages over standard techniques utilizing a pulmonary artery catheter when determination of cardiac output is thought to be important for patient care in the ICU.
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